Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Bispecific monoclonal antibodies (bsAbs)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Bispecific monoclonal antibodies (bsAbs) are molecules designed to recognize two distinct antigens or epitopes
Rodrigues Mantuano et al. 2020

Bispecific monoclonal antibodies (bsAbs) could be used to direct immune cells to Tumor-associated carbohydrates (TACA)-expressing tumors.
Mantuano et al. 2020

Bispecific monoclonal antibodies (bsAbs) designed to target lectins including Siglecs are currently under investigation
Rodrigues Mantuano et al. 2020

Many patients do not respond to [Immune checkpoint inhibitors (ICIs…

References (Sources)

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2
Hoseini et al. 2017 Oncoimmunology 6: e1320625
CD16xCD33 bispecific killer cell engager (bike) activates NK cells against primary MDS and MDSC CD33+ targets
Gleason et al. 2014 Blood 123: 3016-26
Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies
Bachanova et al. 2015 Clin Cancer Res 21:1267-72
Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells
Arndt et al. 2013 Leukemia 27: 964-7
Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in MUC1 positive tumor cells
Li et al. 2018 PLoS One 13: e0191024
T Cell-Redirecting Strategies to ‘STAb’ Tumors: Beyond CARs and Bispecific Antibodies
Blanco et al. 2019 Trends in Immunology 40: 243
Review
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
Rodrigues Mantuano et al. 2020
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Links

Bispecific monoclonal antibody - Wikipedia